[神経膠芽腫の患者における生存率に対するTumor Treating Field［腫瘍治療装置の名称］＋テモゾロミド対テモゾロミド単独の効果：無作為化臨床試験] med. app.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

著者: Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z
掲載誌: JAMA 2017; 318 (23): 2306-2316
RISフォーマットで参考文献をダウンロード

ばく露